Title: 10 minutes read

China is the world’s second-largest liver transplant country (after the United States) [1], and the world’s largest pediatric liver transplant center is at Shanghai Renji Hospital — Academician Xia Qiang’s team has completed over 3,800 pediatric liver transplants cumulatively [2]. For international patients, China’s liver transplant advantage centers on family Living Donor Liver Transplant (LDLT) — a family member serves as the donor and travels with the patient to China. Clinical capability is in the global top tier, and pricing runs approximately 1/5 to 1/8 of US pricing. This article walks through China’s liver transplant regulatory framework, leading centers, the practical access pathway for international patients (focused on the LDLT family-donor model), pricing comparisons, and clinical data.

China’s Global Position in Liver Transplant

Scale data [1]:

  • World’s second-largest liver transplant country (after the US)
  • Approximately 6,170 cases in 2019 (most recent verifiable official data)
  • US 2024: 10,660 cases

Regulatory framework [3]:

  • 2007: State Council issued the Regulations on Human Organ Transplantation
  • May 1, 2024: New Regulations on Human Organ Donation and Transplantation took effect (State Council Decree No. 767)
  • Strictly prohibits organ trade
  • Requires voluntary, unpaid donation
  • Can only be performed at government-certified transplant centers
  • COTRS system (China Organ Transplant Response System) has provided unified allocation since 2013

Practical implication for international patients: China’s liver transplant program operates within a strict regulatory framework — the viable pathway for international patients is primarily Living Donor Liver Transplant (LDLT), where a family member serves as the liver donor and travels to China together with the patient. This is the compliant, safe, and publicly documented model with established case precedent.

Living Donor Liver Transplant (LDLT) vs Deceased Donor Liver Transplant (DDLT)

Living Donor Liver Transplant (LDLT):

  • A healthy adult donates a portion of their liver (typically 30–60%)
  • The donor is typically a direct family member of the patient (parent, spouse, child, sibling)
  • Both donor and recipient livers regenerate to normal volume within 4–8 weeks
  • China has strict medical and ethical evaluation requirements for living donors
  • The primary viable pathway for international patients

Deceased Donor Liver Transplant (DDLT):

  • From citizens who donated after cardiac (DCD) or brain (DBD) death
  • Allocated through the COTRS system based on MELD score, blood type, region, and waiting time
  • Chinese DDLT is primarily allocated to Chinese citizens — practical feasibility for international patients through COTRS is limited
  • Not the primary pathway recommended in this article

This is why this article focuses on LDLT — the family living donor model has clear regulatory support, world-class technical capability, and documented international patient case experience.

China’s Leading Liver Transplant Centers

Shanghai Renji Hospital (Shanghai Jiao Tong University) — Academician Xia Qiang’s Team [2]

  • World’s largest pediatric liver transplant center
  • Cumulatively >3,800 pediatric liver transplants
  • Over 3,200 cases in the past decade
  • Has treated 55–60+ international pediatric patients (from Malaysia, Philippines, Indonesia, Mongolia, and others)
  • Completed the first liver transplant for a Filipino pediatric patient in February 2025 (with the mother as donor) [4]
  • Operates a full International Medical Department with 10+ years of experience serving international pediatric patients

Tianjin First Central Hospital, Oriental Organ Transplant Center — Professor Shen Zhongyang’s Team [5]

  • One of China’s largest adult liver transplant centers
  • Cumulative 4,103 cases through 2011
  • Reduced hepatitis B recurrence rate from >80% to <5% (significant technical breakthrough)
  • Long-standing experience receiving international adult liver transplant patients

Sun Yat-sen University 1st Affiliated Hospital Organ Transplant Center [6]

  • High-volume program
  • International leader in normothermic perfusion / ischemia-free liver transplant technology (Professor He Xiaoshun’s team)
  • 5-year survival ~61.5%
  • International cooperation base

Zhejiang University 1st Affiliated Hospital — Academician Zheng Shusen’s Team [7]

  • Birthplace of the Hangzhou Criteria — China’s expanded selection standard for HCC liver transplant
  • Hangzhou Type A HCC 5-year recurrence-free survival 69.5%
  • Significant academic contribution: enables more HCC patients to benefit from liver transplant

West China Hospital [8]

  • Completed approximately 1,700 liver transplants over the past 20 years (~600 LDLT)
  • 5-year survival 80.5% for benign liver disease
  • National leader in adult LDLT

Beijing Tsinghua Changgung Hospital — Academician Dong Jiahong

  • Precision liver surgery center
  • JCI-accredited hospital
  • Strong international service capability

Shanghai Eastern Hepatobiliary Surgery Hospital (legacy of Academician Wu Mengchao)

  • Primarily liver resection-focused (>5,000 annual cases)
  • National hepatobiliary surgery center

Beijing Friendship Hospital

  • Liver transplant center in operation
  • IMD serves international patients

Recommendations for international patients:

  • Pediatric liver transplant (especially biliary atresia, metabolic liver diseases) → Renji Hospital (absolute first choice, most international case experience)
  • Complex adult liver transplant → Renji, Tianjin Oriental Organ Transplant Center, Sun Yat-sen 1st
  • HCC liver transplant (expanded Hangzhou Criteria cases) → Zhejiang 1st
  • Hepatitis B-related liver transplant → Tianjin (international leader in HBV recurrence management)
  • International service experience → Renji IMD, Tsinghua Changgung, Beijing Friendship IMD

Major Indications for Liver Transplant

Pediatric:

  • Biliary atresia (most common indication for infant liver transplant)
  • Metabolic liver diseases (Wilson disease, tyrosinemia, glycogen storage disease, etc.)
  • Acute liver failure
  • Pediatric liver tumors
  • Congenital hepatic fibrosis

Adult:

  • Cirrhosis with decompensation (HBV, HCV, alcoholic, autoimmune, etc.)
  • Hepatocellular carcinoma (HCC) — must meet transplant criteria
  • Acute liver failure
  • Cholestatic liver diseases (PBC, PSC, etc.)
  • Metabolic liver diseases

HCC Liver Transplant Criteria: Milan vs Hangzhou

Hepatocellular carcinoma (HCC) is a common indication for liver transplant, but patients must meet specific criteria — patients exceeding standards typically have high post-transplant recurrence and poor survival.

Comparison of mainstream international criteria [7]:

Standard Year Selection Criteria (Simplified) HCC 5-year Overall Survival
Milan Criteria 1996 Single ≤5cm or ≤3 tumors with max ≤3cm, no vascular invasion ~70%
UCSF Criteria 2001 Single ≤6.5cm or ≤3 tumors with max ≤4.5cm, total diameter ≤8cm 76.9%
Hangzhou Criteria (Type A) 2008 Incorporates AFP + histologic grade, expands selection 51.5% 66.7% (Type A)

Clinical significance of Hangzhou Criteria:

  • Compared with Milan Criteria, it enables 51.5% more HCC patients to benefit from liver transplant
  • By incorporating tumor biology (AFP + histologic grade) rather than just tumor size and count
  • Hangzhou Type A 5-year OS 66.7% — slightly below UCSF, but for patients exceeding Milan, this means access to liver transplant

Practical implication for international patients: if you or a family member is an HCC patient excluded from liver transplant under Milan Criteria in your home country, evaluation under the Hangzhou Criteria at Zhejiang 1st may offer an opportunity.

International Patient Pathway: LDLT with Family Donor

Typical operational model (based on Renji case experience):

Step 1 · Pre-travel evaluation (4–8 weeks)

  • Complete medical records, liver function, imaging, tumor markers (if HCC) sent to Chinese IMD
  • Renji and other centers conduct indication assessment
  • Simultaneously identify potential family donor (typically parent, child, spouse, sibling)
  • Donor preliminary blood type matching + health evaluation

Step 2 · On-site evaluation upon arrival (1–2 weeks)

  • Patient arrival + inpatient evaluation
  • Donor arrival + complete donor evaluation: liver function, liver volume, vascular anatomy, blood type confirmation, psychological evaluation, ethics committee review
  • Chinese regulations require donor approval through medical evaluation + ethics committee review

Step 3 · Liver transplant surgery (1 day)

  • Donor surgery: removal of portion of liver (typically right lobe or left lateral segment)
  • Recipient surgery: removal of diseased liver, implantation of donor liver
  • Total surgical time 6–12 hours

Step 4 · Post-operative recovery (4–6 weeks inpatient)

  • ICU monitoring 1–2 weeks
  • Anti-rejection medication management
  • Anti-infection management
  • Liver function recovery monitoring
  • Donor typically discharged within 1–2 weeks

Step 5 · Discharge and long-term follow-up (≥3 years)

  • High-frequency follow-up for first 4–6 weeks post-discharge
  • Lifelong anti-rejection medication
  • Long-term liver function monitoring, anti-rejection medication adjustment

Total time in China: typically 8–12 weeks (including evaluation, surgery, post-operative recovery, and initial follow-up)

Pricing Comparison: China vs the US vs Europe vs Asia

Country / Center Liver Transplant All-Inclusive Cost (USD)
China (international patient all-inclusive) ~$120,000 – $180,000
United States $150,000 – $800,000+ (2020 procedure + care approximately $878,400)
Germany $250,000 – $300,000
Korea (Samsung Seoul, Asan) $128,000 – $158,000
India (Mumbai, New Delhi) $28,000 – $45,000
UK NHS Free for citizens; international self-pay data not publicly disclosed

Sources: ClinicsOnCall, Resolve Medical Bills, Bookimed, Medigence, PSRI Hospital [10]

Core comparison:

  • China is approximately 1/5 to 1/8 of US pricing — substantial difference
  • Comparable pricing to Korea
  • Approximately 40–50% less than Germany
  • 3–4× higher than India — but China’s clinical capabilities, regulatory framework, and anti-rejection technical maturity meaningfully exceed India’s

Typical cost breakdown (estimated at the ~$150K median):

  • Surgery + ICU costs: ~$60K
  • Hospital ward, nursing, imaging, lab: ~$30K
  • Donor surgery and care: ~$25K
  • Anti-rejection medications (initial period): ~$15K
  • International patient coordination, interpretation, accommodation: ~$20K

Clinical Data: Survival Rates at China’s Leading Centers

Renji Hospital pediatric liver transplant [2]:

  • Cumulative >3,800 cases
  • 55–60+ international pediatric patients
  • Pediatric 1-year survival (industry standard) >90%
  • 5-year survival (industry standard) >80%

Zhejiang 1st HCC liver transplant [7]:

  • Within Milan Criteria 5-year OS ~76.9%
  • Within UCSF Criteria 5-year OS ~77.6%
  • Within Hangzhou Type A 5-year OS 66.7%

Sun Yat-sen 1st comprehensive liver transplant [6]:

  • 5-year OS ~61.5%

West China Hospital [8]:

  • Benign liver disease 5-year OS 80.5%

Important note (as in Article 22): 5-year overall survival (5-year OS) is the international standard outcome measure, reflecting the proportion of patients alive five years post-transplant, including those still on treatment, those with stable disease, and those with controlled recurrence — not a simple “cure rate.”

Comparison with international leading centers: China’s leading centers’ pediatric liver transplant 5-year OS (>80%) and adult benign liver disease 5-year OS (~80%) are on par with Western leading centers (Mayo, UCSF, UPMC, etc.).

Side Effects, Risks, and Long-term Management

Surgery-related risks:

  • Bleeding, infection, biliary complications
  • Rejection (acute vs chronic)
  • Graft dysfunction
  • Perioperative mortality: adult LDLT ~1–3%, pediatric LDLT ~1–2%

Long-term management:

  • Anti-rejection medications for life (tacrolimus, mycophenolate, steroids, etc.)
  • Long-term regular monitoring of liver function, drug levels, rejection markers
  • Long-term infection risk (especially first 3–6 months post-op)
  • Long-term cancer risk (secondary malignancies)
  • Chronic kidney injury (anti-rejection medication side effect)

Practical implication for international patients: liver transplant is not “a one-time surgery that solves the problem” — it’s the beginning of lifelong management. After returning home, establishing long-term cooperation with a transplant center in your home country is essential for long-term follow-up. MedCareInChina assists in establishing the bridge between the Chinese primary physician and your home country transplant center for remote communication.

Common Questions

I’m a liver transplant candidate — can I bring a family member as a living donor to China? For pediatric patients and adult patients meeting criteria, this is the most mature pathway China offers international patients. Renji Hospital has 55–60+ international pediatric LDLT cases publicly documented.

How significant is the donor’s surgical risk? LDLT donor mortality is approximately 0.2–0.5% (very low, but not zero); major complications (bleeding, biliary leak, infection) occur in approximately 10–20%. China’s leading LT centers have donor management capability on par with international standards.

Will the donor’s liver recover to normal? Yes. The healthy adult liver has powerful regenerative capability — the donor liver typically recovers to normal volume within 4–8 weeks, with liver function essentially returning to pre-operative levels.

What if I don’t have a suitable family member to donate? DDLT (deceased donor) allocation in China for international patients through the COTRS system has limited practical feasibility — Chinese DDLT is primarily allocated to Chinese citizens. If a suitable family donor is not available, alternative international options should be considered (such as the US UNOS waiting list, Japan/Korea LDLT programs, etc.).

Does the Hangzhou Criteria allow all HCC patients to qualify for liver transplant? No. Hangzhou Criteria expands selection 51.5% beyond Milan, but still has an upper limit — patients exceeding Hangzhou Type A still have high post-transplant recurrence rates. MDT evaluation of your specific case is required.

Can post-transplant follow-up be done in my home country? Yes, and recommended. Anti-rejection medication management is lifelong — after the post-operative period stabilizes in China (1–3 months), follow-up management can transfer to a transplant specialist in your home country. The critical step is establishing immediate post-operative coordination with your home country transplant center — MedCareInChina assists with this transition.

Can life be normal after liver transplant? The vast majority of patients can return to normal life, work, and study within 3–6 months post-transplant. Pediatric patients typically recover well and can attend school and exercise normally.

Can anti-rejection medications be discontinued completely after transplant? Typically no — anti-rejection medication is lifelong. But medication doses and types are gradually optimized over time (from multi-drug combination to single-agent maintenance), with reduced side effects over the years.

Bottom Line

The core value of liver transplant in China for international patients:

  • World’s second-largest liver transplant country, with world-class technical capability
  • Pricing approximately 1/5 to 1/8 of US (~$120K–$180K vs US $150K–$800K+)
  • World’s leading pediatric liver transplant (Renji Hospital Xia Qiang team, 55–60+ international pediatric case successes)
  • Hangzhou Criteria enables patients beyond Milan to access transplant
  • 2024 new regulations ensure compliance, ethics, and transparency

Best-suited international patients for liver transplant in China:

  • Pediatric biliary atresia, metabolic liver disease, acute liver failure patients
  • Adult patients with a suitable family member donor for LDLT
  • HCC patients excluded under their home country’s Milan Criteria but meeting Hangzhou Criteria
  • Patients seeking economically feasible liver transplant options

Key pathway: Living Donor Liver Transplant (LDLT) — family member travels with the patient to China as the liver donor

Total time in China: 8–12 weeks (including evaluation, surgery, post-operative recovery, and initial follow-up)

If you or a family member is a liver transplant candidate, MedCareInChina can facilitate communication with leading centers including Renji, Zhejiang 1st, and Tianjin Oriental — assessing LDLT feasibility based on your condition and family situation, with clear judgment on “whether feasible, who would serve as donor, expected timeline, and estimated cost.”

→ Send your case to hello@medcareinchina.com

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. China’s liver transplant scale and global position — China is the world’s second-largest liver transplant country, approximately 6,170 cases in 2019. Source: AJT https://www.amjtransplant.org/article/S1600-6135(22)14388-1/fulltext ; US 2024 data: OPTN/UNOS report https://hrsa.unos.org/news/organ-transplants-exceeded-48-000-in-2024-a-33-percent-increase-from-the-transplants-performed-in-2023/
  2. Shanghai Renji Hospital pediatric liver transplant center — Academician Xia Qiang’s team, cumulative >3,800 pediatric liver transplants, treated 55–60+ international pediatric patients. Sources: Shanghai government English version https://english.shanghai.gov.cn/en-Latest-WhatsNew/20250312/1f09a4dc0a0447a290bb9670bfdd11ef.html ; China Daily https://www.chinadaily.com.cn/a/202503/11/WS67cff2dfa310c240449da2a9_2.html
  3. China organ transplant regulations — 2007 Regulations on Human Organ Transplantation; May 1, 2024 new Regulations on Human Organ Donation and Transplantation effective. Sources: State Council https://english.www.gov.cn/policies/latestreleases/202312/14/content_WS657a6be9c6d0868f4e8e228c.html ; 2024 AJT commentary https://www.amjtransplant.org/article/S1600-6135(24)00273-9/fulltext
  4. Filipino pediatric LDLT first case — Completed at Renji in February 2025. Source: CGHMC https://cghmc.com.ph/advancing-healthcare-cghmc-and-renji-hospital-perform-first-pediatric-liver-transplant-fora-filipino-patient/
  5. Tianjin First Central Hospital Oriental Organ Transplant Center — Professor Shen Zhongyang’s team, cumulative 4,103 adult liver transplants through 2011. International leader in HBV recurrence management. Source: PubMed https://pubmed.ncbi.nlm.nih.gov/22755414/
  6. Sun Yat-sen 1st ischemia-free liver transplant — Professor He Xiaoshun’s team. 5-year survival ~61.5%. Source: Transplantation Journal https://journals.lww.com/transplantjournal/fulltext/2023/09000/first_affiliated_hospital_of_sun_yat_sen.1.aspx
  7. Zhejiang 1st Hangzhou Criteria — Proposed by Academician Zheng Shusen in 2008. Hangzhou Type A HCC 5-year recurrence-free survival 69.5%. HCC selection criteria comparison (Milan, UCSF, Hangzhou). Sources: Hangzhou Criteria PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8432180/ ; Zheng Shusen bio https://aacrjournals.org/pages/shusen-zheng-bio
  8. West China Hospital Liver Surgery — Completed approximately 1,700 liver transplants over the past 20 years, benign liver disease 5-year survival 80.5%. Source: https://www.wchscu.cn/details/51606.html
  9. China LDLT vs DDLT ratio — CLTR 2011 data: DDLT 92.6%, LDLT 7.4%. In pediatric liver transplant, LDLT ~80%. Source: CLTR 2011 report https://pmc.ncbi.nlm.nih.gov/articles/PMC3924683/
  10. International liver transplant pricing comparison — China ~$120K–$180K; US $150K–$800K+; Germany $250K–$300K; Korea $128K–$158K; India $28K–$45K. Sources: ClinicsOnCall https://clinicsoncall.com/en/clinics/country-china/oncology/procedure-liver-transplantation/ ; Resolve Medical Bills https://www.resolvemedicalbills.com/blog/the-true-cost-of-a-liver-transplant-in-the-us ; Bookimed Germany https://us-uk.bookimed.com/clinics/country=germany/procedure=liver-transplantation/ ; Medigence Korea https://medigence.com/hospitals/transplants/liver-transplant/south-korea ; PSRI India https://psrihospital.com/liver-transplant-cost-in-india-from-diagnosis-to-recovery/